Diagnostic accuracy of 2-[fluorine-18]fluro-2-deoxy-D-glucose positron emission tomography imaging in nonsquamous tumors of the head and neck

Investigative Radiology

Volumn 38, Issue 9, 2003, Pages 593-601

  Bui, Chuong D ^a   Ching, Alex S C ^b   Carlos, Ruth C ^a   Shreve, Paul D ^a   Mukherji, Suresh K ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b NORTH DISTRICT HOSPITAL   (Hong Kong)

Author keywords

Head and neck tumor; Lymph nodes; Melanoma; Positron emission tomography; Thyroid cancer

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CERVICAL LYMPH NODE; CLINICAL ARTICLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; FEMALE; FOLLOW UP; HEAD AND NECK TUMOR; HISTOPATHOLOGY; HUMAN; LYMPH NODE METASTASIS; MALE; MELANOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; THYROID TUMOR;

EID: 0042328255     PISSN: 00209996     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.RLI.0000077126.42858.92     Document Type: Article

References (35)

1. Ak I, Stokkel MPM, Pauwels EKJ. Positron emission tomography with 2[18F]fluoro-2-deoxy-glucose in oncology. Part II. The Clinical value in detecting and staging primary tumors. J Cancer Res Clin Oncol. 2000;126:560-574.
2. Gambhir SS, Czemin J, Schwimmer J, et al. A tabulated summary of the FDG PET literature. J Nucl Med. 2001;42:1S-93S.
3. Minn H, Paul R, Ahonen AJ. Evaluation of treatment response to radiotherapy in head and neck cancer with fluorine-18 flurodeoxyglucose. J Nucl Med. 1988;29:1521-1525.
4. McGuirt WF, Greven K, Willams D, et al. PET scanning in head and neck oncology: a review. Head Neck. 1998;20:208-215.
5. Yasuda S Ide M Shohtsu A. Cancer screening with whole-body FDG PET. In: Ruhlmann J, Oehr P, Biersack HJ, eds. PET in oncology. Springer-Verlag;Berlin: 1999:179-183.
6. Thrail JH, Ziessman HA. Fluorine-18 fluorodeoxyglucose tumor imaging. In: Nuclear medicine: the requisites, 2nd ed. St. Louis: Mosby; 2001:207-214.
7. Oehr P. Metabolism and transport of glucose and FDG. In: Ruhlmann J, Oehr P, Biersack HJ, eds. PET in oncology. Springer-Verlag;Berlin: 1999:43-52.
8. Jabour BA, Choi Y, Hoh CK. Extracranial head and neck: PET imaging with 2-[f-18]fluoro-2-deoxy-D-glucose and MR imaging correlation. Radiology. 1993;186:27-35.
9. Yeo JS, Chung JK, SO Y, et al. F-18-fluorodeoxyglucose positron emission tomography as a presurgical evaluation modality for 1-131 scan-negative thyroid carcinoma patients with local recurrence in cervical lymph nodes. Head Neck. 2001;23:94 -103.
10. Teknos TN, Rosenthal EL, Lee D, et al. Positron emission tomography in the evaluation of stage III and IV head and neck cancer. Head Neck. 2001;23:1056-1060.
11. Terhaard CH, Bongers V, van Rijk PP, et al. F-18-fluoro-deoxy-glucose positron-emission tomography scanning in detection of local recurrence after radiotherapy for laryngeal/pharyngeal cancer. Head Neck. 2001;23:933-941.
12. Shreve PD, Anzai Y, Wahl RL. Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. Radiographics. 1999;19:61-77.
13. Graham MM. Is quantitation necessary for oncological PET studies? Against. Eur J Nucl Med. 2002;29:135-138.
14. Keys JW Jr. SUV: standard uptake or silly useless value? J Nucl Med. 1995;36:1836-1839.
15. Brock CS, Meikle SR, Price P. Does fluorine-18 fluorodeoxyglucose metabolic imaging of tumours benefit oncology? Eur J Nucl Med. 1997;24:691-705.
16. Lowe VJ, Dunphy FR, Varvares M, et al. Evaluation of chemotherapy response in patients with advanced head and neck cancer using [F-18]fluorodeoxyglucose positron emission tomography. Head Neck. 1997;19:666-674.
17. Haberkom U, Strauss LG, Reisser C. Glucose uptake, perfusion, and cell proliferation in head and neck tumors: relation of positron emission tomography to flow cytometry. J Nucl Med. 1991;32:1548-1555.
18. Dietlein M, Scheidhauer K, Voth E, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography and iodine-131 whole-body scintigraphy in the follow-up of differentiated thyroid cancer. Eur J Nucl Med. 1997;24:1342-1348.
19. Hooft L, Hoekstra OS, Deville W, et al. Diagnostic accuracy of 18F-fluorodeoxyglucose positron emission tomography in the follow-up of papillary or follicular thyroid cancer. J Clin Endocrinol Metab. 2001;86:3779-3786.
20. Grunwald F, Kalicke T, Feine U, et al. Fluorine- 18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study. Eur J Nucl Med. 1999;26:1547-1552.
21. Feine U, Leitzenmayer R, Hanke J, et al. Fluorine- 18-FDG and iodine131 - iodide uptake in thyroid cancer. J. Nucl Med. 1996;37:1468-1472.
22. Chung JK, So Y, Lee JS, et al. Value of FDG PET in papillary thyroid carcinoma with negative 131 I whole-body scan. J Nucl Med. 1999;40:986-992.
23. Szakall S Jr, Esik O, Bajzik G, et al. 18-FDG PET detection of lymph node metastases in medullary thyroid carcinoma. J Nucl Med. 2002;43:66-71.
24. McGuirt WF, Keyes JW Jr, Greven KM, et al. Preoperative identification of benign versus malignant parotid masses: a comparative study including positron emission tomography. Laryngoscope. 1995;105:579-584.
25. Anzai Y, Minoshima S, Wolf GT, et al. Head and neck cancer: detection of recurrence with three-dimensional principal components analysis at dynamic FDG PET. Radiology. 1999;212:285-290.
26. Mijnhout GS, Hoekstra OS, van Tulder MW, et al. Systemic review of the diagnostic accuracy of (18)F-fluorodeoxyglucose positron emission tomography in melanoma patients. Cancer. 2001;15:1530-1542.
27. Wagner JD, Schauwecker DS, Davidson D, et al. FDG-PET sensitivity for melanoma lymph node metastasis is dependent on tumor volume. J Surg Oncol. 2001;77:237-242.
28. Goerres GW, Stoeckli SJ, von Schulthess GK, et al. FDG PET for mucosal malignant melanoma of the head and neck. Laryngoscope. 2002;112:381-385.
29. Schwarzbach MH, Dimitrakopoulou-Strauss A, Mechtersheimer G, et al. Assessment of soft tissue lesions suspicious for liposarcoma by F18-deoxyglucose (FDG) positron emission tomography (PET). Anticancer Res. 2001;21:3609-3614.
30. Chummun S, McLean NR, Kelly CG, et al. Adenoid cystic carcinoma of the head and neck. Br J Plast Surg. 2001;54:476-480.
31. Urquhart A, Berg R. Hodgkin's and Non-Hodgkin's lymphoma of the head and neck. Laryngoscope. 2001;111:1565-1569.
32. Naumann R, Vaic A, Beuthien-Baumann B, et al. Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin's disease and non-Hodgkin's lymphoma. Br J Haematol. 2001;115:793-800.
33. Wirth A, Seymour JF, Hicks RJ, et al. Fluorine- 18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma. Am J Med. 2002;112:262-268.
34. Hoffman M, Kletter K, Diemling M, et al. Positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose (F18-FDG) does not visualized extranodal B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT)-type. Ann Oncol. 1999;10:1185-1189.
35. Strauss LG. Fluorine-18 deoxyglucose and false-positive results: a major problem in the diagnostics of oncological patients. Eur J Nucl Med. 1996;23:1409-1415.